Predictions
Fresenius Medical Care AG & Co KGaA ST
Start price
Target price
Perf. (%)
€29.85
13.11.22
13.11.22
-
13.12.22
13.12.22
1.61%
14.12.22
14.12.22
Known brand
Could be worthwhile Investment >10% per year
Carl Zeiss Meditec AG
Start price
Target price
Perf. (%)
€163.60
05.12.21
05.12.21
€180.00
05.12.22
05.12.22
-21.45%
06.12.22
06.12.22
Could be worthwhile Investment >10% per year
Carl Zeiss Meditec AG
Start price
Target price
Perf. (%)
€179.00
06.11.21
06.11.21
-
06.11.22
06.11.22
-32.77%
07.11.22
07.11.22
Fresenius Medical Care AG & Co KGaA ST
Start price
Target price
Perf. (%)
€36.50
22.08.22
22.08.22
€66.00
22.08.23
22.08.23
-8.22%
03.09.22
03.09.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€25.58
22.08.22
22.08.22
€44.00
22.08.23
22.08.23
-5.00%
03.09.22
03.09.22
Could be very worthwhile Investment >20% year
Capable Management
Good culture
Innovative
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€35.03
23.12.21
23.12.21
-
23.12.22
23.12.22
-28.09%
25.08.22
25.08.22
Carl Zeiss Meditec AG
Start price
Target price
Perf. (%)
€147.00
01.02.22
01.02.22
€180.00
01.08.22
01.08.22
-3.71%
01.08.22
01.08.22
Could be very worthwhile Investment >20% year
Standard Investments for future growth
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€36.70
27.01.22
27.01.22
€42.00
27.07.22
27.07.22
-24.49%
27.07.22
27.07.22
Could be worthwhile Investment >10% per year
Fair valuation
High dividend yield expected
Small challenges to pay loans and raise capital
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€43.94
08.07.21
08.07.21
€55.00
08.07.22
08.07.22
-34.74%
08.07.22
08.07.22
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€36.17
01.02.21
01.02.21
€26.00
30.06.22
30.06.22
-10.17%
19.05.22
19.05.22
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€40.55
04.05.21
04.05.21
€55.00
04.05.22
04.05.22
-11.84%
05.05.22
05.05.22
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Undervalued